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Summary
Objective: The present analysis examined the exposure-response relationship by
means of the predose everolimus concentration (Cmin) and the seizure response in
patients with tuberous sclerosis complex–associated seizures in the EXIST-3 study.
Recommendations have been made for the target Cmin range of everolimus for thera-
peutic drug monitoring (TDM) and the doses necessary to achieve this target Cmin.
Methods: A model-based approach was used to predict patients’ daily Cmin.
Time-normalized Cmin (TN-Cmin) was calculated as the average predicted Cmin in
a time interval. TN-Cmin was used to link exposure to efficacy and safety end
points via model-based approaches. A conditional logistic regression stratified by
age subgroup was used to estimate the probability of response in relation to expo-
sure. A multiplicative linear regression model was used to estimate the exposure-
response relationship for seizure frequency (SF). An extended Cox regression
model was used to link exposure to the time to first adverse event.
Results: There was a strong, consistent, and highly significant relationship
between everolimus exposure and efficacy, measured by TN-Cmin and SF, regard-
less of patient’s age and concomitant use of cytochrome P450 3A4 (CYP3A4)
inhibitors/inducers. Results of an extended Cox regression analyses indicated that
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twofold increases in TN-Cmin were not associated with statistically significant
increases in the risk of stomatitis or infections.
Significance: The recommended TDM is to target everolimus Cmin within a range
of 5-7 ng/mL initially and 5-15 ng/mL in the event of an inadequate clinical
response, and safety is consistent with previous reports. Starting doses depend on
age and the concomitant use of CYP3A4/P-glycoprotein inducers/inhibitors.
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1 | INTRODUCTION
Tuberous sclerosis complex (TSC) is a rare autosomal
dominant multisystem disorder, resulting from mutations in
one of the TSC genes, TSC1 or TSC2. Epilepsy is the most
common neurologic symptom of TSC and occurs in 80%-
90% of patients.1,2 Approximately two-thirds of patients
experience seizure onset in the first year of life, often as
infantile spasms or partial seizures.3,4 In adults with TSC
and no prior history of seizures, nearly 12% develop epi-
lepsy at some point in time.3 The management of TSC-
associated refractory seizures may include antiepileptic
drugs (AEDs), ketogenic diet, epilepsy surgery, and vagus
nerve stimulation.5 However, existing treatments are often
ineffective and >60% of patients develop treatment-refrac-
tory seizures.4
Dysregulation and hyperactivation of the mechanistic
target of rapamycin (mTOR) pathway are responsible for
the pathophysiology of TSC. This has led to the use of
mTOR inhibitors to treat the various manifestations of
TSC. Everolimus, an mTOR inhibitor, has been approved
by regulatory authorities for treatment of TSC-associated
subependymal giant cell astrocytoma (SEGA), angiomy-
olipomas, and epilepsy (European Union approval).6–8 A
recent phase 3 study, EXIST-3 (EXamining everolimus In
a Study of Tuberous sclerosis complex), compared the effi-
cacy and safety of 2 trough exposure levels (Cmin) of
adjunctive everolimus with placebo in patients with TSC
and treatment-resistant focal epilepsy.9 Based on the posi-
tive results of this trial, the European Commission
approved everolimus as an adjunctive treatment for patients
aged 2 years and older with refractory partial-onset seizures
associated with TSC.9 Findings from the EXIST-3 study
showed that everolimus led to a statistically significant and
clinically meaningful reduction in seizure frequency (SF)
and response rate with a favorable benefit-risk profile that
improves with ongoing treatment.8 In this study, everoli-
mus trough concentration (Cmin) was found to be correlated
with seizure outcomes (response rate and median percent-
age reduction in SF).8
In patients with TSC, a substantial variability of everoli-
mus Cmin levels was observed. This is likely due to everoli-
mus being metabolized by cytochrome P450 3A4 (CYP3A4)
and is a substrate of the P-glycoprotein (PgP) transporter.
Many of the AEDs typically used in these patients are either
inducers or substrates of these enzymes. Other medications
can inhibit the activity of the CYP P450 system, and thereby
inhibit the clearance of everolimus. In addition, volume of
Key Points
• Epileptic seizures are one of the most common
presenting symptoms of TSC, affecting 80%-90%
of patients; >60% of patients with TSC develop
treatment-refractory seizures
• Dysregulation and hyperactivation of the mTOR
pathway are responsible for the pathophysiology
of TSC; this led to the use of everolimus, an
mTOR inhibitor for the treatment of various
manifestations of TSC
• The EXIST-3 study demonstrated a strong, con-
sistent, and highly statistically significant rela-
tionship between everolimus PK exposure and
seizure frequency response or postbaseline sei-
zure frequency across all age groups
• Everolimus is primarily metabolized by CYP3A4
and is a substrate of the PgP transporter; many
of the AEDs typically used in patients with TSC
and seizures are either inducers or substrates of
these enzymes, and hence monitoring of everoli-
mus blood Cmin levels is recommended to opti-
mize therapy
• The recommendation based on the present results
is to target a concentration range of everolimus
of 5-15 ng/mL for patients with TSC-associated
refractory seizures
• The safety of everolimus is consistent with the
known safety profile of everolimus in TSC
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distribution and metabolism change with advancing age; this
effect is especially prominent in a pediatric population.
Therefore, monitoring of everolimus blood Cmin levels may
provide important clinical information and allow for opti-
mization of therapy. In the previously reported studies in
TSC patients with SEGA, durable response rates were
achieved with everolimus by targeting Cmin of 5-15 ng/
mL.6,10,11 We evaluated the effect of age on the pharmacoki-
netic (PK) profile of everolimus and exposure-response rela-
tionship in patients with TSC-associated refractory seizures.
Based on the results of PK and exposure-response analyses,
recommendations for the target Cmin range for therapeutic
drug monitoring (TDM) in patients with TSC-associated
refractory seizures of different age groups and the doses to
achieve the target Cmin have been explored.
2 | MATERIALS AND METHODS
The details of the EXIST-3 study design have been reported
previously.8 Briefly, EXIST-3 was a 3-arm, prospective, ran-
domized, multicenter, double-blind, placebo-controlled,
phase 3 study comparing the efficacy and safety of 2 everoli-
mus treatment arms targeting either low everolimus exposure
(3-7 ng/mL; LE) or high everolimus exposure (9-15 ng/mL;
HE) with a placebo arm, in patients with TSC who had refrac-
tory partial onset seizures and were on a stable regimen of
AEDs prior to the start of everolimus treatment. The study
included an initial 8-week baseline phase, followed by an 18-
week core phase, and a 48-week extension phase. Patients
were randomly assigned to placebo, LE, and HE arms.
Patients were stratified by age subgroups (<6 years, 6 to
<12 years, 12 to <18 years, and ≥18 years). Everolimus was
taken daily with food or consistently without food according
to label prescriptions. As the safety of everolimus was well
known, only Cmin was collected in this study with the primary
aim of the TDM. PK samples were excluded if they were not
taken under the correct time window, impacted by vomiting
episodes, or not a steady state. Because of the exclusion of
unlikely values and the review of results by an expert PK sci-
entist, the observed Cmin was considered the true Cmin. Dose
adjustments to attain the target Cmin were performed during
the first 6 weeks of the core phase, and as needed during the
subsequent 12-week maintenance period. The primary effi-
cacy end point was change from baseline in SF for each of
the 2 everolimus Cmin target ranges compared with placebo
after the 12-week maintenance period of the core phase. SF
corresponds to the ratio between the number of seizures and
the number of days on which seizure information was known
within the same period of time (baseline or maintenance
phase). The change of SF from baseline was expressed both
as response rate and as median percentage reduction in SF.8
A patient was considered to be a responder if the patient
achieved ≥50% reduction from baseline in average weekly
partial onset SF during the maintenance period of the core
phase. Independent ethics committees and/or local ethics
review boards approved the protocol, and all patients or their
guardians provided written informed consent.
2.1 | PK analysis
Clinical sites collected blood samples prior to the administra-
tion of that day’s study medication (trough PK) in all patients
during the 6-week titration period of the core phase and for-
warded them to a central laboratory for determination of ever-
olimus Cmin. After the completion of the titration period,
patients continued their current dose level during the 12-week
maintenance period. Trough PK blood samples were collected
every 4 weeks during the maintenance period. In addition,
trough everolimus levels were collected every 2 weeks after
any everolimus dose adjustments as well as after any initia-
tion, discontinuation, or dose adjustment of a CYP3A4/PgP
inducer/inhibitor. PK statistical analyses were performed on
those PK samples obtained prior to dose administration, 20-
28 hours after the patient’s last dose, at steady state, and in
the absence of vomiting within 4 hours after previous dose.
Based on the dose-proportionality characteristics of
everolimus, a modified power model12 was used to predict
a daily Cmin. The power model was expressed as a linear
mixed effect model with a random effect to account for
interpatient variability and the patient’s daily leading dose
and age subgroup as fixed effects to capture the impact of
the most immediate dose on the concentration levels
adjusted by the patient’s age. Both the Cmin and leading
dose parameters were transformed into logarithmic scale
prior to the modeling step. The age subgroup (<6 years, 6
to <12 years, 12 to <18 years, and ≥18 years) reflected the
strata used at the time of randomization.
Time-normalized Cmin (TN-Cmin) was an estimate of the
daily Cmin for a patient averaged over a time interval. Time-
normalized Cmin was linked to the efficacy or safety end
point measured over the same time interval. A conditional
logistic regression model stratified by age subgroup was
used to estimate the probability of an efficacy response in
relation to exposure. The model estimated the odds of a
response per a twofold increase in everolimus exposure. A
linear regression model was used to estimate postbaseline SF
in relation to exposure over the 12-week maintenance period
of the core phase. The model was multiplicative in nature, as
both variables (postbaseline SF and TN-Cmin) were trans-
formed in logarithmic scale. Based on this model, the mini-
mum efficacious everolimus concentration was predicted.
The minimum efficacious concentration refers to the mini-
mum everolimus concentration that resulted in a level of effi-
cacy higher than that experienced by patients on the placebo
arm in terms of SF reduction. To characterize the exposure-
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safety relationship, the time to first event of the selected
adverse events (AEs) in relation to everolimus exposure was
estimated using an extended Cox model, stratified by age
subgroup, with TN-Cmin as a time-varying covariate over 4
prespecified time intervals. The 4 time intervals were defined
according to the study design: the titration and maintenance
periods of the core phase and the titration and maintenance
periods of the extension phase. Using everolimus exposure
as a time-dependent covariate allowed a better characteriza-
tion of the impact of any change in everolimus exposure
over time due to dose titration or interruption.
3 | RESULTS
A total of 366 patients were randomized to receive placebo
(n = 119), LE everolimus (n = 117), or HE everolimus
(n = 130). Detailed patient baseline characteristics have
been reported previously.8 The median age of patients in the
LE arm was 9.7 years (range = 2.2-56.3 years), and in the
HE arm it was 10.1 years (range = 2.3-50.5 years). Eighty-
two percent of the study population was <18 years of age.
Overall, the demographic and disease characteristics were
well balanced among the treatment arms. Body surface area
(BSA) was noted to increase up to the age of 18 years, and
thereafter remained relatively stable (Figure S1).
3.1 | Cmin during the core phase
The BSA-adjusted median dose received by patients in the
LE arm was 5.2 mg/m2/d (range = 1.3-14.5 mg/m2), and in
the HE arm it was 7.5 mg/m2/d (range = 1.4-24.4 mg/m2).
The median Cmin values for the LE and HE arms were sim-
ilar at week 1. Over time, median Cmin values for the LE
FIGURE 1 Everolimus observed Cmin
concentrations (ng/mL) during the core
phase. A, Observed Cmin by randomized
everolimus treatment arms. HE, high
exposure; LE, low exposure. This figure
shows that everolimus LE arm achieved the
target Cmin of 3-7 ng/mL starting at week
1, with the median Cmin maintained within
the target range during the core phase. The
everolimus HE arm had similar Cmin values
as the LE arm at week 1 because the same
starting doses were administered to both
treatment arms, and then gradually
increased toward the end of the core phase.
Overlapping but notable differences were
seen in the exposures achieved in the
everolimus LE and HE arms. B, Proportion
of patients by exposure ranges based on
everolimus (EVE) observed Cmin. This
figure displays the proportion of patients
with their observed everolimus Cmin ranges
during the core phase. The majority of the
patients had their everolimus Cmin within
the target trough range of 5-15 ng/mL. The
red arrows denote the 2 exposure ranges of
everolimus patients who were targeted to
achieve LE, 3-7 ng/mL and HE, 9-15 ng/
mL
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and HE arms increased gradually until the end of the core
phase due to dose titrations (Figure 1). The median Cmin
observed at the end of the core phase in patients random-
ized to the LE arm was 5.1 ng/mL (range = 1.4-25.3 ng/
mL), and in the HE arm it was 8.3 ng/mL (range = 0.8-
22.0 ng/mL). There was an overlap in Cmin range across
different arms, but notable differences in the exposures
were achieved in the LE and HE arms (Figure 1A). The
majority of patients had their Cmin within the range of 5-
15 ng/mL (Figure 1B). Approximately 60% of patients in
the HE arm were found to be below the lower limit of the
target Cmin range (9 ng/mL) at week 18 (Figure 1B). In all
age ranges, there is a trend indicating an increase in Cmin
with increasing doses (Figure 2).
3.2 | Effect of age and concomitant use of
CYP3A4 inducers on everolimus Cmin
There was a large interpatient variability in the dose-nor-
malized Cmin that decreased with increasing age (Figure S2).
Irrespective of the assigned exposure group, median dose-
normalized Cmin was higher for the patients who were in
the younger age groups, whereas the values were similar
for patients who were age ≥ 12 years. Figure S2 and
Table S1 show that concomitant administration of a
CYP3A4/PgP inducer decreased the median dose-normal-
ized Cmin of everolimus in all age groups.
3.3 | Cmin-efficacy relationship analysis
A trend indicative of better SF response and better percent-
age SF reduction from baseline at higher TN-Cmin values
was evident (Figure 3A-C). The response rates were 29.9%
(n = 147, 95% confidence interval [CI] = 22.7%-38.0%) in
the exposure range of 3-7 ng/mL compared with 44.2%
(n = 52, 95% CI = 30.5%-58.7%) and 50% (n = 30, 95%
CI = 31.3%-68.7%) in the exposure ranges of >7 to <9 ng/
mL and 9-15 ng/mL, respectively. The response rate in
patients with TN-Cmin < 3 ng/mL was similar to that of
patients in the placebo arm (14.0% vs 15.0%, respectively).
Similarly, the median percentage reduction from baseline in
SF was 35.6% (n = 147, 95% CI = 24.4%-41.9%) in the
exposure range of 3-7 ng/mL compared with 39.7%
(n = 52, 95% CI = 28.0%-62.8%) and 47.7% (n = 30, 95%
CI = 36.5%-66.3%) in the exposure ranges of >7 to <9 ng/
mL and 9 to 15 ng/mL, respectively. A conditional logistic
regression stratified by age subgroup showed that a twofold
increase in TN-Cmin was associated with a 2.17-fold
increase (95% CI = 1.339-3.524) in the odds of a response.
In addition to TN-Cmin, baseline SF was also a significant
factor (with an odds ratio of 0.978, 95% CI = 0.959-
0.998), indicating that patients with higher baseline SF had
more difficulty becoming a responder.
3.4 | Minimum efficacious concentration
Results of a linear regression model predicting the log of
absolute SF during the maintenance period of the core
phase indicated that for a twofold increase in TN-Cmin
there was a statistically significant 28% reduction (95% CI
= 12%-42%) in postbaseline SF. Both baseline SF and TN-
Cmin were significant factors.
Based on this multiplicative linear regression model, it
was predicted that a TN-Cmin of 5.3 ng/mL was the lowest
FIGURE 2 Relationship between
predose everolimus concentrations (Cmin)
and dose (mg/m2) in patients with tuberous
sclerosis complex (TSC)-associated seizures
in all age ranges. This figure shows a trend
indicating an increase in predose
everolimus Cmin with increase in doses for
patients with TSC seizures across all the
age ranges
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everolimus exposure for which the reduction from baseline
in SF was higher than the expected reduction in patients
taking placebo. It was with an everolimus exposure of
5.3 ng/mL that the 95% CI of predicted change from base-
line SF in patients treated with everolimus (0.537-0.695)
did not overlap with the 95% CI of predicted change from
baseline SF in patients treated with placebo (0.696-0.879;
Figure 3D).
3.5 | Cmin-safety relationship
AEs were consistent with the known safety profile of ever-
olimus. The most frequently reported AEs of any grade in
our study were stomatitis (placebo, 9%; LE, 55%; HE,
64%), diarrhea (placebo, 5%; LE, 17%; HE, 22%), and
nasopharyngitis (placebo, 16%; LE, 14%; HE, 16%).8 The
nature and pattern of AE frequencies during the core phase
were similar for patients with TN-Cmin exposures in the LE
and HE groups (Table S2). Stomatitis of grade 3 or 4
severity was reported in 3% of patients in the LE group
and 4% of patients in the HE group. The other most fre-
quent grade 3 or 4 AEs reported with everolimus (occur-
ring in >2 patients) included neutropenia (LE, 2%; HE,
2%), pneumonia (LE, 1%; HE, 2%), and irregular
FIGURE 3 Everolimus exposure-response relationships. A,
Effect of everolimus time-normalized (TN)-Cmin on response rate.
Error bars represent 95% confidence intervals of median. TN-Cmin
denotes an estimated average of Cmin across the maintenance period
of the core phase. This figure shows an improvement in seizure
response rates with an increase in everolimus TN-Cmin. Reduction in
seizure frequency (SF) among patients with an average exposure of
<3 ng/mL was similar to that in patients treated with placebo. B,
Effect of everolimus TN-Cmin on median percentage reduction in SF.
Error bars represent 95% confidence intervals of median. This figure
depicts an improvement in the median percentage reduction in SF
with increase in everolimus TN-Cmin. Reduction in SF among patients
with an average exposure of <3 ng/mL was similar to that in patients
treated with placebo. C, Relationship between median percentage
reduction in SF and TN-Cmin. The straight line in the figure stands
for a linear regression. This figure depicts the percentage reduction in
SF with increase in everolimus TN-Cmin in both everolimus low-
exposure and high-exposure arms. The modeling data confirm that a
twofold increase in TN-Cmin reduced postbaseline SF by 28%. D,
Baseline-adjusted change of SF by TN-Cmin during the maintenance
period of the core phase. This figure presents a model-based approach
to determine the lowest TN-Cmin for which a response in SF
(represented by fold change from baseline in SF) was statistically
different between everolimus and placebo. The predicted fold change
from baseline in SF for patients taking placebo was presented as a
straight line at 0.25 with light gray colored 95% confidence interval
(CI) representing the 15% reduction in SF demonstrated in the
placebo treatment arm with zero exposure to everolimus. The
predicted fold change from baseline reduction in SF for patients
taking everolimus increases as TN-Cmin increases. A TN-Cmin of
5.3 ng/mL was considered the lowest everolimus exposure level for
which 95% CI of predicted change from baseline SF (0.537-0.695)
did not overlap with the 95% CI of predicted change from baseline
SF of placebo (0.696-0.879), indicating this as the lower bound of the
therapeutic range
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menstruation (HE only, 2%). Although the percentage of
patients reporting AEs of special interest (AESIs) was
lower at TN-Cmin < 3 ng/mL than those reporting at higher
TN-Cmin, the percentages of patients reporting AESIs at
TN-Cmin ranges of 3 to <5 ng/mL and 5-15 ng/mL were
similar (Table 1). Results of extended Cox regression anal-
yses of the time to first event of stomatitis and infections
and infestations versus TN-Cmin indicated that TN-Cmin
was associated with an increase in the risk of either of
these events during the core phase (stomatitis: hazard ratio
[HR] = 1.092, 95% CI = 0.866-1.376; infections and infes-
tations: HR = 1.060, 95% CI = 0.85-1.33). However, these
effects were not statistically significant.
4 | DISCUSSION
Everolimus is eliminated in humans primarily by metabo-
lism via CYP3A4.13 The activity of CYP3A4 is extremely
weak or absent in the fetus and begins to increase after
birth to reach 30%-40% of the adult activity after 1 month
and 50% of adult levels between 6 and 12 months of
age.14–19 As the CYP3A4 isozyme capacity starts maturing
in newborns to full capacity during adolescence, clearance
of everolimus also changes with age. Due to the different
rates of increase in body size and liver enzyme capacity
with age, patterns of change in everolimus clearance with
age are different based on whether clearance is normalized
to BSA. Because BSA increases up to the age of 18 years
and thereafter remains largely constant (Figure S1), differ-
ences in the everolimus clearance across different age
ranges were observed in our study. Based on dose-normal-
ized Cmin values in patients of different age ranges, everoli-
mus clearance values were lower in patients of age ranges
1 to <3 years and ≥3 to <6 years, whereas everolimus
clearance values normalized to BSA were lower in patients
of age ranges ≥12 to <18 years and ≥18 years. Dose-nor-
malized Cmin (Cmin/dose) is inversely related to apparent
clearance, and so the relationship between dose-normalized
Cmin and age is a mirror image of the relationship between
clearance and age. The patterns of the change in everoli-
mus clearance with age, using dose-normalized Cmin as the
surrogate, were similar in patients with TSC-associated
SEGA20 and patients with TSC-associated refractory sei-
zures. In addition to the effect of age on everolimus blood
concentrations, patients with TSC-associated refractory sei-
zures receive concomitant administration of CYP3A4
enzyme-inducing AEDs (EIAEDs), which might affect the
clearance of everolimus in blood. As expected, patients
with concomitant administration of CYP3A4/PgP inducers
had lower dose-normalized Cmin across all age ranges.
Because both age and use of CYP3A4 EIAED concomitant
medication can impact everolimus clearance, TDM is rec-
ommended to maintain Cmin within a target concentration
range for patients with TSC seizures. A target concentra-
tion range of 5-15 ng/mL is recommended for the follow-
ing reasons. (1) The time-normalized Cmin of 5.3 ng/mL
was the threshold concentration, above which the 95% CI
of predicted change from baseline SF does not overlap with
the 95% CI of predicted change from baseline seizure of
placebo patients, and hence this indicates that Cmin of
5.3 ng/mL is the lower bound of the therapeutic range. (2)
In addition, the seizure response was numerically superior
at the TN-Cmin range of 5-15 ng/mL than <5 ng/mL and a
higher Cmin was associated with a better seizure response.
Also, there were limited data on Cmin values >15 ng/mL,
which limited the ability to assess the safety of Cmin expo-
sure >15 ng/mL, and hence this indicates an upper bound
of the therapeutic range, at least preliminarily until further
results should become available. (3) Although the percent-
age of patients reporting AESI was lower at TN-Cmin <
3 ng/mL than those reporting at higher TN-Cmin, the
TABLE 1 Number and percentage of patients reporting adverse events of special interest by time-normalized Cmin range (≥5% frequency)
Adverse event, n (%)
<3 ng/mL,
n = 15
3 to <5 ng/mL,
n = 89
5-15 ng/mL,
n = 139
>15 ng/mL,
n = 2
Placebo,
n = 119
Cytopenia 2 (13) 8 (9) 7 (5) 2 (100) 9 (7.6)
Dyslipidemia in pediatric population [<18 years old] 1 (7) 13 (15) 16 (12) 1 (50) 5 (5.2)a
Hemorrhages 0 (0) 6 (7) 16 (12) 0 (0) 4 (3.4)
Hyperglycemia/new onset of diabetes 0 (0) 15 (17) 23 (17) 1 (50) 9 (7.6)
Hypersensitivity 0 (0) 12 (14) 23 (17) 0 (0) 8 (6.7)
Hypophosphatemia 1 (7) 1 (1) 0 (0) 0 (0) 0 (0)
Female infertility [including amenorrhea] 0 (0) 4 (5) 3 (2) 1 (50) 4 (10.8)b
Postnatal developmental toxicity 0 (0) 1 (1) 1 (1) 1 (50) 2 (2.1)a
Stomatitis 7 (47) 52 (58) 84 (60) 2 (100) 11 (9.2)
aPercentage calculated based on the number of patients aged <18 years (n = 97 for the placebo arm).
bPercentage calculated based on the number of female patients aged 10-55 years (n = 37 for the placebo arm).
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percentages of patients reporting AESIs at TN-Cmin ranges
of 3 to <5 ng/mL and 5-15 ng/mL were similar. No nota-
ble differences in overall safety were observable across the
3-15 ng/mL Cmin exposure range. (4) The majority of
observed Cmins in this study were in the range of 5-15 ng/
mL, the safety and tolerability profile of everolimus
observed in the study was consistent with prior experience
in the TSC setting,7,10 and the grading (severity) of most
events was modest (typically grade 1 or 2).8
It was observed at week 1 of the core phase in the
EXIST-3 study that the median Cmin for adult patients was
<5 ng/mL and was the lowest among patients of other
ranges. To provide a simpler age-based starting dose scheme
and to increase the Cmin level after the starting dose for adult
patients, a starting dose scheme, based on 2 categories of age
rather than 3, has been proposed; a starting dose of 6 mg/m2
is recommended for patients aged <6 years and 5 mg/m2 for
those ≥6 years of age, who are not receiving EIAEDs or
other CYP3A4/PgP inducers. For those who are receiving
concomitant CYP3A4/PgP inducers (carbamazepine,
oxcarbazepine, phenobarbital, phenytoin, primidone, cloba-
zam, topiramate), a dose of 9 mg/m2 is recommended for
those aged <6 years and 8 mg/m2 for those ≥6 years of age
(Table 2). In addition, a flexible titration dose scheme of 1-
4 mg is recommended, in comparison to the fixed 2-mg titra-
tion dose (or 4 mg for patients with concomitant use of a
CYP3A4/PgP inducer) used in the EXIST-3 study. The fixed
2-mg titration dose could be too low for some patients (eg,
patients with larger body size and/or patients with high ever-
olimus clearance). The flexible titration dose scheme could
potentially reduce the number of titration steps to attain a
Cmin within the target range. The recommended starting dose
and titration dose scheme of 1-4 mg based on simple dose
proportionality is supported by a simulation (Figure 4) pre-
dicting that 25-75 percentile of the predicted Cmin is within
the target 5-15 ng/mL range after 1-2 dose titrations. We
illustrate the use of the 1- to 4-mg flexible titration dose with
2 examples. For a patient who receives a starting dose of
4 mg/d and achieves a steady state concentration of 4 ng/
mL, to reach everolimus concentration >5 ng/mL (eg, 6 ng/
mL), the new dose would be 6 mg/d (an increase by 2 mg/
d). Similarly, if a patient receives a starting dose of 8 mg/d
and achieves a steady state concentration of 4 ng/mL, the
new dose would be 12 mg/d (an increase of 4 mg/d).
In conclusion, the present results demonstrate that tar-
geting an everolimus Cmin within the range of 5-7 ng/mL
initially and 5-15 ng/mL in the event of an inadequate clin-
ical response has a favorable risk-benefit profile in patients
with TSC-associated refractory seizures. Starting doses to
achieve such a target TDM range with flexible titration
TABLE 2 Recommended starting dose for treatment of patients
with tuberous sclerosis complex–associated seizures
Age
range,
y
Without the concomitant
administration of CYP3A4/
PgP inducer
With the concomitant
administration of
CYP3A4/PgP inducer
<6 6 mg/m2 9 mg/m2
≥6 5 mg/m2 8 mg/m2
CYP3A4, cytochrome P450 3A4; PgP, P-glycoprotein.
FIGURE 4 Box plots of predicted
predose everolimus concentration (Cmin)
after the starting dose and over 5 dose
titrations by age range based on the
recommended starting dose scheme.
Recommended starting dose scheme: 6 mg/
m2/d and 5 mg/m2/d for patients aged
<6 years and 5 mg/m2/d for patients > or =
6 years ≥ 6 years, respectively. Titration
dose scheme: 1-4 mg. The figure shows
that 25-75 percentile of the predicted Cmin
was within the target 5-15 ng/mL range
after 1-2 dose titrations
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increments of 1-4 mg are recommended based on age and
status of CYP3A4/PgP inducers.
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